Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.
Pharmalucence receives FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.